Autres langues Skye Bioscience, Inc.

Actions

EMBI

US83086J2006

Temps réel estimé Cboe BZX Autres places de cotation 21:06:09 26/06/2024			Varia. 5j.	Varia. 1 janv.
7,88 ^USD	0,00%		-11,81%	+189,52%

10/06	Skye Bioscience, Inc. concentre sa stratégie et son développement clinique sur le programme métabolique du Nimacimab	CI
10/06	Skye Bioscience arrête le développement d'un médicament contre les maladies oculaires après l'échec d'une étude à mi-parcours	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Skye Bioscience, Inc.(NasdaqGM:SKYE) added to S&P TMI Index	24/06
Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program	10/06
Skye Bioscience to stop eye disease drug development after failing mid-stage study	10/06
Skye Bioscience to discontinue development of eye disease treatment	10/06
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting	13/05
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	23/04
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	12/04
Skye Bioscience Uplists to The Nasdaq Global Market	10/04
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	03/04
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Skye Bioscience, Inc. announced that it has received $40 million in funding	13/03
Skye Bioscience Announces $40 Million Private Placement Equity Financing	11/03
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	11/03
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	04/03
Skye Bioscience Announces Board Changes	04/03
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	12/02
Skye Bioscience to Present at Oppenheimer Investor Conference	07/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Skye Bioscience, Inc.

Actions

EMBI

US83086J2006

Autres langues

Filtres